

Arrowhead Pharmaceuticals, Inc. Investor Relations Department 225 South Lake Avenue Suite 1050 Pasadena, CA 91101 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: ARWR	
Last Trade:	3.55
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.04 👚 (+1.140%)
Day Range	3.40 - 3.58
52-Week Range	1.20 - 8.09
Volume	692,300

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAibased therapeutics leverage this natural pathway of gene silencing.

... (more)

Stock Performance



Press Releases [View all]

Sep 14, 2017

Arrowhead Hosts Investor & Analyst R&D

Day to Introduce TRiM™ Platform and Lead

RNAi-based Drug Candidates

Sep 11, 2017

Arrowhead to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference

Sep 1, 2017

<u>Arrowhead Pharmaceuticals to Host R&D</u>
<u>Day on RNAi-Based Therapies</u>

Aug 3, 2017

<u>Arrowhead Reports Fiscal 2017 Third Quarter Results</u>

Jul 27, 2017

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Third Quarter Results

Upcoming Events [View all]

Sep 25, 2017 9:10 AM ET
2017 Cantor Fitzgerald Global Healthcare
Conference

Financials [View all]

Third Quarter Financial Results

Dec 14, 2016

Annual Report (10-K)

Feb 1, 2017

Proxy Statement (DEF 14A)

Aug 3, 2017

Quarterly Report (10-Q)

May 3, 2017

Quarterly Report (10-Q)

Feb 6, 2017

Quarterly Report (10-Q)